Budgetary Impact on a U.S. Health Plan Adopting Abiraterone Acetate Plus Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer

BACKGROUND: Abiraterone acetate, an androgen biosynthesis inhibitor, received FDA approval in 2011 for metastatic castration-resistant prostate cancer (mCRPC) patients who have received prior chemotherapy containing docetaxel. OBJECTIVES: To estimate the projected budgetary impact of adopting abirat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sorensen, Sonja, Ellis, Lorie, Wu, Ying, Hutchins, Valerie, Linnehan, John E., Senbetta, Mekré
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2013
Materias:
Contemporary Subject
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437412/
https://www.ncbi.nlm.nih.gov/pubmed/24156649
http://dx.doi.org/10.18553/jmcp.2013.19.9.799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437412/
https://www.ncbi.nlm.nih.gov/pubmed/24156649
http://dx.doi.org/10.18553/jmcp.2013.19.9.799

Ejemplares similares